Healthleap raised $38 million to expand its AI-driven patient screening platform to identify additional medical conditions, part of a broader wave of funding for AI tools aimed at catching diagnoses earlier.
A Blue Cross Blue Shield Association analysis estimates AI-assisted medical coding tools added roughly $942 million in questionable hospital charges between 2023 and 2025, a claim the American Hospital Association disputes.
PhilHealth is weighing an AI system to catch mismatched lab tests and diagnoses before paying claims, part of a global shift toward pre-payment fraud detection in health insurance.
A new analysis finds most health plans now use AI for prior authorization approvals, but a meaningful share also use it for denials — a distinction advocates say current federal AI policy dangerously fails to make.
Stanford's new Virtual Biotech platform aims to compress drug discovery timelines through AI simulation, an academic counterpart to the wave of commercial AI drug discovery deals reshaping pharma research.
Two large Chinese clinical trials — one on rare disease diagnosis, one an 8,240-patient orthopedic study — offer some of the most rigorous real-world evidence yet on AI's clinical impact, with results still pending.
Teladoc's new hospital ambient scribe and AKASA's autonomous coding platform both push AI documentation tools into higher-stakes settings with less human oversight than earlier assistive versions.
Mass General Brigham's new AI intake agent inside MyChart aims to help patients navigate primary care access, part of a broader trend of embedding AI assistance directly into existing patient portal software.
SimBioSys has won FDA clearance for TumorSight Risk, an AI tool that turns a single MRI into a five- and ten-year recurrence forecast for early-stage breast cancer patients.
A five-center JAMA study found ambient AI scribes cut documentation time by 16 minutes per visit, but researchers say the burnout gains are concentrated among clinicians who actually use the tools regularly.